# NI-0401 in Active Crohn's Disease

> **NCT00630643** · PHASE1,PHASE2 · COMPLETED · sponsor: **Light Chain Bioscience - Novimmune SA** · enrollment: 40 (actual)

## Conditions studied

- Moderate to Severe Crohn's Disease

## Interventions

- **BIOLOGICAL:** NI-0401 (anti-CD3 mAB)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00630643
- **Lead sponsor:** Light Chain Bioscience - Novimmune SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2008-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630643, "NI-0401 in Active Crohn's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00630643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*